Patients who received a Biomet M2a Magnum hip replacement will be eligible to pursue claims against the manufacturer if their hip device fails, despite a settlement reached earlier this year. In February, Biomet agreed to pay $56 million to metal hip patients who received a faulty M2a magnum hip replacement.
The ongoing settlement will cover roughly 2,400 Biomet lawsuits alleging that the company released a defective device which caused injuries. However, should a patient who is not a part of the settlement suffer similar injuries from a Biomet M2a magnum metal-on-metal hip replacement, he or she will still be eligible to file a lawsuit against the company.
The Biomet M2a Magnum hip implant was approved under the Food and Drug Administration’s 510(k) approval process, which allowed the company to forego serious clinical testing for potential defects. The device has since been found to cause serious injuries, including tissue damage and toxic levels of metal in the blood stream.